Sanction: The Paris Court of Appeal reduces the penalty imposed on a pharmaceutical company by €4 million, but essentially confirms the French Competition Authority’s analysis on the delay in generic entry (Janssen-Cilag, Johnson & Johnson)

*This article is an automatic translation of the original article in French, provided here for your convenience. Read the original article. On 11 July 2019, the Paris Court of Appeal handed down a ruling in the case of the delay in the entry of generics of Durogesic. It will be recalled that by a decision rendered on December 20, 2017In its decision of 25 March 2008, the Competition Authority sanctioned the laboratory Janssen-Cilag, as the perpetrator, and its parent company Johnson & Johnson - imputability obliges - to the tune of EUR 25 million, for having carried out, from 25 March 2008 to mid-August 2009, that is to say, for 16 months, two practices constituting a complex and continuous infringement aimed at preventing, then to limit the penetration of generic competitors of